Rewind Therapeutics

Biotech company Rewind Therapeutics wants to develop new therapies for diseases where the insulating myelin layer around the nerves is affected, such as in Multiple Sclerosis (MS).

Existing therapies only alleviate symptoms. Rewind Therapeutics aims to repair the damage to the myelin itself, thus slowing or even curing the disease. This would be a very important breakthrough for the many MS patients.

In early 2018, Rewind received a powerful capital injection of €15.2 million. Together with CD3, three major life sciences investors took the lead: Boehringer Ingelheim Venture Fund (BIVF), Merck Ventures (MV) and PMV. The funding was also supported by the KU Leuven Gemma Frisius Fund (GFF).
Rewind Therapeutics will use the money to bring its first product to the clinic and identify new drug candidates.